GlobeNewswire

Minerva Neurosciences Names Devin Smith Senior Vice President, General Counsel

Share

WALTHAM, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Devin W. Smith as Senior Vice President and General Counsel.  Mr. Smith will manage all corporate legal affairs and provide business counsel on a broad range of strategic, tactical and operational issues related to the growth of the Company and the development of its portfolio of CNS products. 

Mr. Smith was previously General Counsel and Company Secretary at Stallergenes Greer plc, a global biopharmaceutical company focused on allergy immunotherapy products.  His responsibilities encompassed support for commercial and medical activities, business development, mergers and acquisitions, corporate governance, management of claims, intellectual property, litigation and investigations, compliance and finance.  Mr. Smith joined Stallergenes from EMD Serono, Inc, the biopharmaceutical division of Merck KGaA, where he led the North American legal department as Vice President and General Counsel.  Prior to that, Mr. Smith was a partner at the international law firm of Nixon Peabody LLP, where he represented emerging and established life science, information technology and manufacturing businesses.

"Devin Smith brings a deep understanding of corporate strategic development to his position as the Company's General Counsel, and we welcome him to the Minerva management team," said Rick Russell, President of Minerva.

Mr. Smith received his law degree (cum laude) from Suffolk University Law School and a B.A. in political science from the University of North Carolina - Chapel Hill.

About Minerva Neurosciences:

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases.  Minerva's proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson's disease.  Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV."  For more information, please visit www.minervaneurosciences.com

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to Mr. Smith's positive impact on us, including as we proceed through clinical trials.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, Mr. Smith's and our ability to perform as expected.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed with the Securities and Exchange Commission on May 3, 2018.  Copies of reports filed with the SEC are posted on our website at  www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

Contact:

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

GINA TRICOT ROLLS OUT RFID MAKING INVENTORY ACCURACY AND SUSTAINABILITY A PRIORITY  23.8.2019 11:00:00 CESTPress release

Nordic ID, a Finnish technology company, known for innovative PaaS-solutions for item tracking and management, partners with Swedish clothing company Gina Tricot for real-time inventory solutions to be rolled out in more than 180 stores. Gina Tricot and Nordic ID will roll out the cloud-based inventory solution to track all its merchandise and to create real time visibility to inventories at various locations. This will enable outstanding inventory accuracy and allow the Swedish fashion house to respond with needed actions even faster. With the help of the RFID-based inventory solution, stores can take inventory on average 1-2 times a week, allowing optimal stock balance. Sustainability is an integral part of Gina Tricot operations and this solution will give insights needed to further optimize processes. The Nordic ID inventory solution will also help to continuously track inter-store deliveries. By implementing RFID, Gina Tricot targets an inventory accuracy of 99,5 %. Typically inve

Oasmias depåbevis avnoterade från NASDAQ i USA23.8.2019 10:30:00 CESTPressemelding

Oasmia Pharmaceutical AB har tidigare kommunicerat att bolaget avser att avnotera sina amerikanska depåbevis från Nasdaq Capital Market ("NASDAQ") i USA. Avlistningen är nu genomförd. Huvudsyftet med avnoteringen är att minska komplexiteten i finansiell rapportering och administrativa kostnader. Oasmias stamaktier fortsätter att handlas på NASDAQ Stockholm. Innehavare av depåbevis/ADS som vill fortsätta att inneha Oasmia-aktier i form av ADS behöver inte vidta några åtgärder. Oasmia kommer att upprätthålla en amerikansk mottagningsfacilitet för att göra det möjligt för investerare att inneha Oasmia-aktier i form av ADS och fortsätta att handla dessa värdepapper på OTC-marknaden. Dessa ADS:er kommer automatiskt att övergå till det nya ADR-programmet i samband med avlistningen och handlas under en ny ticker som ska utses. De investerare som innehar amerikanska ADS:er/depåbevis har möjlighet att lösa in dessa mot stamaktier i Oasmia som handlas på Nasdaq Stockholm. Mer information finns p

Oasmia ADSs delisted from NASDAQ in the US23.8.2019 10:30:00 CESTPress release

Oasmia Pharmaceutical AB has previously communicated that the company intends to delist its American Depositary Shares (“ADS”) from the Nasdaq Capital Market (“NASDAQ”) in the US. The delisting is now effective. The main purpose of the delisting is to reduce complexity in financial reporting and administrative costs. Oasmia’s ordinary shares will continue to trade on Nasdaq Stockholm. Holders of ADSs that wish to continue to hold Oasmia shares in the form of ADSs do not have to take any action. Oasmia will maintain an American Depositary Receipt facility to allow investors to hold Oasmia shares in the form of ADSs, and to continue to trade those securities on the over-the-counter market. ADSs will automatically transition to the new ADR program in connection with the delisting and will be traded under a new ticker to be designated. Holders of ADSs may also choose to transition from holding ADSs to holding ordinary shares listed on Nasdaq Stockholm. Read more on Oasmia website. https://

Statkraft kjøper tysk elbilladeselskap23.8.2019 10:01:00 CESTPressemelding

(Teisnach/Düsseldorf/Oslo, 23. august 2019) Statkraft har kjøpt det tyske elbilladeselskapet E-WALD GmbH. Oppkjøpet styrker Statkrafts posisjon i det tyske og europeiske elbillademarkedet etter fjorårets investering i München-baserte eeMobility GmbH. E-WALD GmbH, også med base i Bayern, har en sterk posisjon innen hurtiglading og deling av elbiler. Selskapet driver rundt 300 ladestasjoner og tilbyr elbildeling av omlag hundre biler til selskaper og kommuner med totalt 7000 brukere. Oppkjøpet av E-WALD vil styrke Statkrafts posisjon i Tyskland og komplettere selskapets investering i eeMobility, som utvikler totalløsninger for lading av firmabiler. - E-WALD har et godt utgangspunkt for vekst innen elbillading i Tyskland, og vi ser frem til å bygge selskapet videre og støtte en ambisiøs vekststrategi, sier Bjørn Holsen, direktør for ny forretningsutvikling i Statkraft, Europas største produsent av fornybar energi. - Dette oppkjøpet markerer en viktig milepæl i selskapets utvikling og bekr

Statkraft acquires German EV charging company E-Wald GmbH.23.8.2019 10:01:00 CESTPress release

(Teisnach/Düsseldorf/Oslo, 23 August 2019) Statkraft has acquired the entire shareholding of electric vehicle (EV) charging company E-WALD GmbH. The acquisition further strengthens Statkraft’s position in the German and European EV charging market after it became a majority shareholder in eeMobility in Germany last year. The EV charging company E-WALD GmbH, based in Bavaria, Germany has a strong position in fast charging and electric car sharing services. It operates around 300 charging stations and offers EV leasing services for circa 100 fleet cars to corporations and municipalities with approximately 7000 customers in total. The acquisition of E-WALD will strengthen Statkraft’s position in Germany and complements the company’s position in eeMobility, which provides a full service offering of charging solutions for company car fleets. “E-WALD is well placed for growth within fast charging in Germany and we look forward to build the company further and support its ambitious growth str

Terms for switches in inflation-linked bond SGB IL 310223.8.2019 09:30:00 CESTPress release

The Swedish National Debt Office offers switch auctions in inflation-linked bond SGB IL 3102 with the aim of decreasing the outstanding volume to around SEK 25 billion before the bond’s time to maturity is shorter than one year. The switch auctions will be held on 20, 23 and 24 September. The offered bonds in the switch auctions are SGB IL 3112, SGB IL 3109 and SGB IL 3113. Switches versus SGB IL 3112 and SGB IL 3113 will be price risk neutral 1 while the switch versus SGB IL 3109 will be cash neutral2. Switch auctions Fri 20 September Risk neutral Mon 23 September Cash neutral Tue 24 September Risk neutral SNDO sells bond 3112 3109 3113 SNDO sells amount (SEK mn) 400 250 250 SNDO buys bond 3102 3102 3102 SNDO buys amount (SEK mn) 3 1 800 200 1 400 Time for yield on buy-back loan 10:45 10:45 10:45 Time for auction cut-off 11:00 11:00 11:00 Time for auction result 11:03 11:03 11:03 The switches were announced in the publication Central Government Borrowing – Forecast and Analysis 2019:2